|Harvard Medical School, Ph.D|
Kevin J. Bitterman, Ph.D. is a Principal at Polaris Venture Partners. Kevin joined Polaris in 2004 and focuses on investments in the life sciences. Prior to joining Polaris, Kevin completed his Ph.D. in genetics at Harvard Medical School. His doctoral research focused on small molecule regulation of the sirtuin class of protein deacetylases. Kevin has authored papers in the journals Nature, Science and Molecular Cell and is a co-founder of Genocea Biosciences, Parasol Therapeutics and Sirtris Pharmaceuticals. Kevin currently represents Polaris as a Director of Biolex Therapeutics, TARIS Inc., Follica Inc., Genocea Biosciences, Parasol Therapeutics and Solace Pharmaceuticals. Additionally, Kevin is a Board Observer to Pulmatrix Inc.